Nasser, N.J.; Sun, K.; Scanlon, K.M.; Mishra, M.V.; Molitoris, J.K.
Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare. Cancers 2022, 14, 864.
https://doi.org/10.3390/cancers14040864
AMA Style
Nasser NJ, Sun K, Scanlon KM, Mishra MV, Molitoris JK.
Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare. Cancers. 2022; 14(4):864.
https://doi.org/10.3390/cancers14040864
Chicago/Turabian Style
Nasser, Nicola J., Kai Sun, Karen M. Scanlon, Mark V. Mishra, and Jason K. Molitoris.
2022. "Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare" Cancers 14, no. 4: 864.
https://doi.org/10.3390/cancers14040864
APA Style
Nasser, N. J., Sun, K., Scanlon, K. M., Mishra, M. V., & Molitoris, J. K.
(2022). Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare. Cancers, 14(4), 864.
https://doi.org/10.3390/cancers14040864